XML 62 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue - Janssen Biotech Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Collaborative Arrangements and Co-Promote Agreement          
Revenue   $ 12,427 $ 12,838 $ 43,915 $ 44,633
Percentage of profit share 67.00%     65.00%  
Revenue from the recognition of previously deferred revenue   8,836 7 $ 21,661 39
Research and development   52,006 52,693 152,223 149,079
Janssen          
Collaborative Arrangements and Co-Promote Agreement          
Upfront payment receivable $ 100,000        
Revenue   8,807 8,866 21,522 21,044
Percentage of profit share 33.00%        
Maximum potential payments receivable $ 900,000        
Collaborative arrangement, opt in fee 200,000        
Collaborative arrangement, future development and commercialization milestones $ 700,000        
Revenue from collaborative arrangements   8,800   21,500  
Research and development   11,500 $ 10,500 29,100 $ 28,100
Deferred revenue   $ 47,400   $ 47,400